Quarterly ResultApr 29, 2026, 07:02 AM
AMRN Q1 Revenue +7% to $45.1M; Net Loss $(10.5)M; Positive Cash Flow
AI Summary
Amarin Corporation plc reported Q1 2026 financial results, with total net revenue increasing 7% to $45.1M and net loss narrowing 33% to $(10.5)M. The company generated positive cash flow for the second consecutive quarter and reiterated its expectation for full-year positive cash flow. International sales, particularly from its European partnership with Recordati, showed early measurable progress, while the U.S. franchise maintained market share with VASCEPA-branded prescriptions rising 17% YoY.
Key Highlights
- Total Net Revenue increased 7% to $45.1M in Q1 2026.
- Net Loss narrowed 33% to $(10.5)M, or $(0.03) per share.
- Generated positive cash flow for the second consecutive quarter.
- Operating Expenses decreased 31% to $29.1M.
- U.S. product revenue was $35.6M, consistent with prior year.
- Europe product revenue was $4.9M, down 9% due to model transition.
- Rest-of-World product revenue grew to $2.8M from $0.
- Cash and investments rose 9% to $307.8M.
- Licensing & Royalties increased 84% to $1.8M.